Loading…
Loading…
Structured register of government actions in the geoeconomic space — export controls, tariffs, sanctions, FDI screening, subsidies, industrial-policy laws — cross-referenced into the country, minerals, and ETF surface. Charter: docs/IPTM_CHARTER.md.
Severity 1-5 is the qualitative impact rating (1=minor, 5=structural). The bilateral-trade-grounded quant scorer is the next IPTM milestone. RBI (Register Breadth Index) is a complementary structural-breadth indicator from scripts/py/iptm/breadth.py; divergence between RBI and severity is itself informative (high-sev / low-RBI = strategic chokepoint; low-sev / high-RBI = broad but shallow). Every action has at least one primary source URL. Verify-or-don't-file. See also themes, timeline, graph, sankey, map, country exposure, sector exposure, material exposure (+ graph), weekly briefs, portfolio scan, escalation monitor, trans-shipment hubs. Internal triage tools (RSS-poller candidate feed, source-feed health) live under /admin/candidates + /admin/sources. Subscribe via Atom feed (accepts ?country=CN, ?material=lithium, ?issuer=BIS, ?type=export_control, ?etf=SOXX, ?company=NVDA, ?minSeverity=4, ?year=2026, ?q=…) or pull /api/iptm/actions.
On 26 January 2026 Beijing's Dongcheng District (via the Zhongguancun Science Park Dongcheng Zone Management Committee and the district Science and Technology Commission) issued Notice 东城园文〔2026〕2号, "Several Measures of Beijing Dongcheng District on Promoting High-Quality Development of the Pharmaceutical and Health Industry," effective 25 February 2026. The 14-article package spans seven chapters covering traditional-Chinese-medicine industry development, product-innovation value realisation, digital medical services, innovative-medicine support, and talent services, with cash grants of up to RMB 20 million per project and up to RMB 10 million per year for a single market entity in the medical-device segment. A draft version was open for public comment from 18 December 2025 to 17 January 2026 before formal issuance.
The Hainan Provincial People's Government General Office issued "Several Policy Measures of Hainan Province for Further Supporting High-Quality Development of the Biopharmaceutical Industry" (Qiong Fu Ban [2025] No. 38) on 2025-08-14, effective 2025-09-13 for a three-year term. The package disburses provincial subsidies across the full biopharma value chain — R&D-stage grants, national centralized-procurement awards, international-certification bonuses, platform-investment reimbursement, and traditional-Chinese-medicine insurance-listing awards — leveraging Hainan Free Trade Port status to build a regional biomedical industry cluster.
On 6 September 2024 China's National Development and Reform Commission (NDRC) and Ministry of Commerce (MOFCOM) jointly issued Order No. 23, the Special Administrative Measures (Negative List) for Foreign Investment Access (2024 Edition), effective 1 November 2024. The 2024 list reduces nationwide restrictions from 31 to 29 entries, removing the last two manufacturing- sector restrictions (publication printing must be Chinese-controlled; investment in TCM-decoction steaming/roasting/calcination processes and confidential-formula proprietary Chinese-medicine production prohibited). Restrictions remain in services (telecommunications value-added, healthcare, education) and in 21 prohibited categories (news publishing, postal monopoly, fishing, gene therapy, tobacco). The 2021 edition is repealed on the same date.